IN2015KN00350A - - Google Patents

Download PDF

Info

Publication number
IN2015KN00350A
IN2015KN00350A IN350KON2015A IN2015KN00350A IN 2015KN00350 A IN2015KN00350 A IN 2015KN00350A IN 350KON2015 A IN350KON2015 A IN 350KON2015A IN 2015KN00350 A IN2015KN00350 A IN 2015KN00350A
Authority
IN
India
Prior art keywords
present
cancer
agents
methods
rspo3
Prior art date
Application number
Inventor
Austin L Gurney
Christopher J Bond
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of IN2015KN00350A publication Critical patent/IN2015KN00350A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate ß-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
IN350KON2015 2012-07-13 2013-07-12 IN2015KN00350A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261671421P 2012-07-13 2012-07-13
US201361753184P 2013-01-16 2013-01-16
US201361789156P 2013-03-15 2013-03-15
US201361826747P 2013-05-23 2013-05-23
PCT/US2013/050300 WO2014012007A2 (en) 2012-07-13 2013-07-12 Rspo3 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
IN2015KN00350A true IN2015KN00350A (en) 2015-07-10

Family

ID=49914164

Family Applications (1)

Application Number Title Priority Date Filing Date
IN350KON2015 IN2015KN00350A (en) 2012-07-13 2013-07-12

Country Status (24)

Country Link
US (3) US9181333B2 (en)
EP (1) EP2872175A4 (en)
JP (1) JP6335896B2 (en)
KR (1) KR20150036603A (en)
CN (1) CN104854132A (en)
AU (1) AU2013289990B2 (en)
BR (1) BR112015000776A2 (en)
CA (1) CA2878868A1 (en)
CL (1) CL2015000097A1 (en)
EA (1) EA032038B1 (en)
EC (1) ECSP15005280A (en)
HK (1) HK1208687A1 (en)
IL (1) IL236617A0 (en)
IN (1) IN2015KN00350A (en)
MX (1) MX2015000565A (en)
NI (1) NI201500002A (en)
NZ (1) NZ704269A (en)
PE (1) PE20150360A1 (en)
PH (1) PH12015500084A1 (en)
SG (1) SG11201500233PA (en)
TW (2) TW201906861A (en)
UA (1) UA117659C2 (en)
WO (1) WO2014012007A2 (en)
ZA (1) ZA201500872B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042236A2 (en) 2006-09-29 2008-04-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
DK2173379T3 (en) 2007-07-02 2015-12-07 Oncomed Pharm Inc Compositions and methods for treatment and diagnosis of cancer
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9260519B2 (en) 2011-06-17 2016-02-16 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
EP2731625B1 (en) 2011-07-15 2018-04-18 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
CA2878868A1 (en) 2012-07-13 2014-01-16 Austin L. Gurney Rspo3 binding agents and uses thereof
US20150147333A1 (en) * 2013-10-18 2015-05-28 Genentech, Inc. Anti-rspo antibodies and methods of use
CN106488775A (en) 2014-07-11 2017-03-08 基因泰克公司 NOTCH approach suppresses
WO2016044295A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
MA41123A (en) * 2014-12-02 2017-10-10 Oncomed Pharm Inc POLYTHERAPY FOR CANCER TREATMENT
WO2017040660A1 (en) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN106913880B (en) * 2015-12-24 2021-02-12 上海交通大学 RSPO 1-containing targeted drug delivery system and preparation and application thereof
CN105925576B (en) * 2016-03-24 2018-04-20 嘉兴市第一医院 SiRNA, ShorthairpinRNA and carrier and application for mammal R Spondin3 gene targets
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
WO2018035210A1 (en) * 2016-08-17 2018-02-22 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with an rspo antagonist
EP3720492A4 (en) * 2017-12-07 2021-12-08 National Health Research Institutes Anti-rspo3 antibodies
CN110339364B (en) * 2018-04-02 2021-02-12 上海邦耀生物科技有限公司 LGR4/RSPO blockers in combination with anti-immune checkpoint inhibitors for immunotherapy of tumors
CN110467663B (en) * 2019-06-18 2022-05-10 华南农业大学 Application of RSPO3 gene in sow ovarian granulosa cells
KR102554222B1 (en) * 2023-03-21 2023-07-11 순천향대학교 산학협력단 Novel anti-rspo3 antibodies and uses thereof
CN116769030B (en) * 2023-08-21 2023-10-20 成都大熊猫繁育研究基地 Panda relaxin 3 monoclonal antibody, hybridoma cell strain and application thereof

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US20070124581A1 (en) 1992-05-17 2007-05-31 Reena Khare Cell adhesion and extracellular matrix proteins
JP2001527403A (en) 1997-04-25 2001-12-25 ジェネティックス・インスチチュート・インコーポレーテッド Secreted proteins and polynucleotides encoding them
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
EP1017811A4 (en) 1997-09-24 2002-08-14 Merck & Co Inc G-protein coupled glycoprotein hormone receptor hg38
US20020065394A1 (en) 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
ATE440865T1 (en) 1998-03-26 2009-09-15 Univ Leland Stanford Junior NEW G-PROTEIN-COUPLED MAMMAL RECEPTORS WITH EXTRACELLULAR LEUCINE-RICH REGION
US6485972B1 (en) 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
US20030166047A1 (en) 1999-05-06 2003-09-04 Millennium Pharmaceuticals, Inc. Lgr6 nucleic acids and uses thereof
JP2003505082A (en) 1999-07-26 2003-02-12 ジェネンテック・インコーポレーテッド Novel polynucleotides and their uses
EP1572987A4 (en) 2000-02-03 2005-11-30 Nuvelo Inc Novel nucleic acids and polypeptides
US6824973B2 (en) 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
EP1267616B1 (en) 2000-03-31 2007-08-08 The General Hospital Corporation Methods of increasing hair growth by wnt polypeptide
JP2003530124A (en) 2000-04-05 2003-10-14 麒麟麦酒株式会社 Methods and materials for novel stem cell growth factor-like polypeptides and polynucleotides
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001281791A1 (en) 2000-05-30 2001-12-11 Bayer Aktiengesellschaft Regulation of human lgr4-like g protein-coupled receptor
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2003050502A2 (en) 2001-12-07 2003-06-19 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
US6768004B2 (en) * 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
US20040077048A1 (en) 2002-01-30 2004-04-22 Warren Bridget A. Protein modification and maintenance molecules
US20100292155A1 (en) 2001-03-05 2010-11-18 Arca Biopharma, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US7411052B2 (en) 2001-03-05 2008-08-12 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US20030032034A1 (en) 2001-03-05 2003-02-13 Tang Y. Tom Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
AU2002304249A1 (en) 2001-06-11 2002-12-23 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
ATE440869T1 (en) 2001-06-20 2009-09-15 Fibron Ltd FGFR3 BLOCKING ANTIBODIES, METHOD FOR SCREENING THEREOF, AND USES THEREOF
US20030022217A1 (en) 2001-07-02 2003-01-30 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
CA2458818A1 (en) 2001-08-30 2003-04-10 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
CA2462795A1 (en) 2001-10-03 2003-04-10 Incyte Genomics, Inc. Secreted proteins
US20040197778A1 (en) 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20070237770A1 (en) 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
EP1504099A4 (en) 2001-12-10 2006-05-10 Nuvelo Inc Novel nucleic acids and polypeptides
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
EP1499637A1 (en) 2002-04-26 2005-01-26 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same
EP1380644A1 (en) 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004074436A2 (en) 2003-02-19 2004-09-02 Incyte Corporation Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer
US20050003405A1 (en) 2003-04-30 2005-01-06 Hua-Chien Chen Treatment and diagnostics of cancer
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050054829A1 (en) 2003-07-22 2005-03-10 Wiley Steven R. Compositions and methods relating to TSP-30a, b, c and d
DE10339820A1 (en) 2003-08-22 2005-03-17 Hinzmann, Bernd, Dr. Use of G-protein coupled receptor, GPR49, peptides, protein and nucleic acid, for diagnosis and prognosis of tumors, also in screening for therapeutic and diagnostic agents
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
PT2157192E (en) 2003-10-10 2013-11-28 Deutsches Krebsforsch Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins)
WO2005040828A2 (en) 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
CA2554403A1 (en) 2004-01-27 2005-08-11 Nuvelo, Inc. Gastrointestinal proliferative factor and uses thereof
WO2005074633A2 (en) 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US7572456B2 (en) 2004-09-13 2009-08-11 Macrogenics, Inc. Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
US7439327B2 (en) 2005-01-18 2008-10-21 Nuvelo, Inc. Stem cell factor-like proteins and uses thereof
US20090220495A1 (en) 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)
US20090036369A1 (en) 2005-07-26 2009-02-05 Kirin Pharma Kabushiki Kaisha Anti-tumor agents comprising r-spondins
WO2007030290A2 (en) 2005-09-07 2007-03-15 Maine Medical Center Research Cristin/r-spondin ligands active in the wnt signaling pathway and methods, compositions and kits relating thereto
WO2007100357A2 (en) 2005-10-07 2007-09-07 Nuvelo, Inc. Stem cell factor-like protein scfa1 and uses thereof
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US7723112B2 (en) 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
KR101196184B1 (en) 2006-06-02 2012-11-01 아베오 파마슈티컬즈, 인크. Hepatocyte growth factor hgf binding proteins
BRPI0712222B1 (en) 2006-06-02 2021-10-13 Aveo Pharmaceuticals, Inc. ISOLATED BINDING PROTEIN WHICH BINDS TO HUMAN HEPATOCYTE GROWTH FACTOR (HGF), ITS USE AND METHOD OF PRODUCTION, NUCLEIC ACID, EXPRESSION VECTOR, HOST CELL, AND METHODS TO PRODUCE A VARIABLE REGION POLYPEPTIDE IMMUNOGLOBULIN AND TO PRODUCE A POLYPEPTIDE THAT COMPRISES A VARIABLE REGION OF THE IMMUNOGLOBULIN LIGHT CHAIN
ES2413087T3 (en) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Compositions and methods for the diagnosis and treatment of cancer
AU2007274738B2 (en) * 2006-07-18 2013-11-28 Sanofi-Aventis Antagonist antibody against EphA2 for the treatment of cancer
JP2008044926A (en) 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York SECRETORY PROTEIN RELATED TO Wnt SIGNAL TRANSDUCTION
WO2008042236A2 (en) 2006-09-29 2008-04-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PL2081586T5 (en) * 2006-10-20 2019-04-30 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
WO2008075796A1 (en) 2006-12-21 2008-06-26 Kyowa Hakko Kirin Co., Ltd. Agent for promoting recovery from blood cell depletion
WO2008088524A2 (en) 2006-12-28 2008-07-24 Nuvelo, Inc. Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
BRPI0812562A2 (en) 2007-06-12 2019-09-24 Trubion Pharmaceuticals Inc anti-cd20 therapeutic compositions and methods
DK2173379T3 (en) 2007-07-02 2015-12-07 Oncomed Pharm Inc Compositions and methods for treatment and diagnosis of cancer
CA2700257A1 (en) 2007-10-02 2009-04-09 Hartmut Land Methods and compositions related to synergistic responses to oncogenic mutations
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CN102112492B (en) 2007-11-14 2015-02-25 中外制药株式会社 Diagnosis and treatment of cancer using anti-GPR49 antibody
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc Fibroblast growth factor receptor 3 (fgfr3) binding proteins
WO2010016766A2 (en) 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
JP5941615B2 (en) * 2008-10-31 2016-06-29 東レ株式会社 Method for immunological measurement of human CXCL1 protein
US20120039912A1 (en) 2009-04-15 2012-02-16 Galapagos Sasu Rspondin-3 inhibition in bone disorders
US20120165270A1 (en) 2009-04-27 2012-06-28 Yeon Sook Choi Inhibition of hair follicle growth by the wnt inhibitor dkk1
EP2424567B1 (en) * 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR20120027031A (en) 2009-06-18 2012-03-20 와이어쓰 엘엘씨 Lyophilized formulations for small modular immunopharmaceuticals
WO2011009090A1 (en) * 2009-07-16 2011-01-20 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
ES2573643T3 (en) 2009-12-23 2016-06-09 Deutsches Krebsforschungszentrum Rspo2 and Rspo3 receptors
US8663950B2 (en) 2010-01-11 2014-03-04 Arizona Board Of Regents Production of a monoclonal antibody therapeutic against west nile virus in plants
AU2011215685B2 (en) 2010-02-12 2015-08-20 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
US20150024952A1 (en) * 2010-12-28 2015-01-22 Arlet Alarcon Molecular profiling for cancer
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
ES2788183T3 (en) * 2011-04-28 2020-10-20 Sbi Biotech Co Ltd Anti-human receptor protein tyrosine phosphatase antibody
EP2731625B1 (en) 2011-07-15 2018-04-18 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
CN104080471B (en) 2011-10-14 2018-08-10 诺华股份有限公司 Antibody and method for Wnt approach relevant diseases
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
JP6545959B2 (en) 2012-02-11 2019-07-17 ジェネンテック， インコーポレイテッド R-Spondin rearrangement and method of using the same
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc ANTI-LGR5 AND IMMUNOCATE PLAYERS
CA2878868A1 (en) 2012-07-13 2014-01-16 Austin L. Gurney Rspo3 binding agents and uses thereof
WO2014165232A1 (en) 2013-03-12 2014-10-09 Curegenix, Inc. Compounds for treatment of cancer
WO2014192974A1 (en) 2013-05-30 2014-12-04 株式会社オーダーメードメディカルリサーチ Reagent including anti-lgr6 antibodies for detection and diagnosis of cancer
US20150147333A1 (en) 2013-10-18 2015-05-28 Genentech, Inc. Anti-rspo antibodies and methods of use
MA41123A (en) 2014-12-02 2017-10-10 Oncomed Pharm Inc POLYTHERAPY FOR CANCER TREATMENT
US9777052B2 (en) 2014-12-02 2017-10-03 The Board Of Regents Of The University Of Oklahoma R-spondin variants, compositions, and methods of use

Also Published As

Publication number Publication date
TWI636061B (en) 2018-09-21
TW201906861A (en) 2019-02-16
US20160108130A1 (en) 2016-04-21
PE20150360A1 (en) 2015-03-20
SG11201500233PA (en) 2015-04-29
WO2014012007A2 (en) 2014-01-16
EA032038B1 (en) 2019-03-29
AU2013289990A1 (en) 2015-02-19
KR20150036603A (en) 2015-04-07
JP6335896B2 (en) 2018-05-30
US20170267776A1 (en) 2017-09-21
WO2014012007A4 (en) 2014-05-30
NZ704269A (en) 2016-05-27
ZA201500872B (en) 2016-06-29
EP2872175A4 (en) 2016-04-20
PH12015500084A1 (en) 2015-03-02
US9181333B2 (en) 2015-11-10
UA117659C2 (en) 2018-09-10
BR112015000776A2 (en) 2017-08-15
CN104854132A (en) 2015-08-19
ECSP15005280A (en) 2016-01-29
JP2015529641A (en) 2015-10-08
CL2015000097A1 (en) 2015-07-10
WO2014012007A3 (en) 2014-04-03
TW201416378A (en) 2014-05-01
US20140017253A1 (en) 2014-01-16
IL236617A0 (en) 2015-02-26
HK1208687A1 (en) 2016-03-11
US9598497B2 (en) 2017-03-21
NI201500002A (en) 2015-07-16
EP2872175A2 (en) 2015-05-20
CA2878868A1 (en) 2014-01-16
AU2013289990B2 (en) 2018-06-14
MX2015000565A (en) 2015-04-10
EA201590144A1 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
MX2014000555A (en) Rspo binding agents and uses thereof.
CY1121148T1 (en) VEGF / DLL4 CONNECTING FACTORS AND THEIR USES
PH12018501264A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX2020003719A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer.
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
EA033400B1 (en) Anti-cd3 antibody and use thereof
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
PH12015500297A1 (en) Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
MX2021010672A (en) Diagnosis and therapy of cancer involving cancer stem cells.
SG185638A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SG10201908388UA (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX341076B (en) Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments.
AU2011328009A8 (en) Compounds and methods for treating pain
MY173377A (en) Anti-b7-h3 antibody
EA201390506A1 (en) POLYPEPTIDES THAT BIND THE COMPONENT C5 OF THE HUMAN COMPLEX
WO2011063237A3 (en) Jagged-binding agents and uses thereof
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
BR112016023011A2 (en) gastric cancer treatment
EA201491352A1 (en) METHOD OF TREATMENT OF BREAST CANCER
MX2017001983A (en) Rspo1 binding agents and uses thereof.
TH163450A (en) VEGF / DLL4 adhesion agent and its use
UA112522C2 (en) METHOD OF THERAPY TUMOR THERAPY